| Special Instructions: |
Indications: to support oxygen-carrying capacity, a
physiologically stable medical or surgical patient whose hemoglobin is >7 g/dL
generally does not require a red cell transfusion. Exceptions may be made based
on compromised cardiovascular or to 10 years, and for longer intervals if there
is particular need for specific units. *****red blood cells deglycerolized is
the form in which cryo-preserved red cells (red blood cells frozen) are
available for infusion. Red blood cells deglycerolized contain 80% or more of
the red cells in the original unit, and have approximately the same expected
post transfusion survival as red blood cells. This product's use should be
restricted to red cells with unusual antigenic phenotypes and for autologous
donations when liquid-preserved blood cannot fulfill demands. This product may
also be useful to patients with clinically significant immune reactivity against
IgA. This product carries the risk of intravascular hemolysis if
deglycerolization has been inadequate. One donated unit can meet the needs of
many patients. *red blood cells are prepared from blood collected into any of
the anticoagulant-preservative solutions approved by the FDA, and separated from
the plasma by centrifugation or sedimentation. Separation may be done at any
time during the allowable storage interval ("shelf life"). At present,
anticoagulant citrate dextrose solutions, usp (acd-a and acd-b) are approved
products that are seldom used. **red blood cells (adenine saline added) are
prepared by centrifuging whole blood to remove as much plasma as possible, and
replacing the plasma with an additive solution that contains some combination of
dextrose, adenine, sodium chloride, and either monobasic sodium phosphate (as-3)
or mannitol (as-1 and as-5); the hematocrit is usually between 55 and 65%. Red
cells in an additive solution have lower viscosity than red blood cells, and
flow through administration systems in a manner more comparable to that of whole
blood. Red cells stored with an additive solution have a shelf life of 42 days
at 1-6 °C. ***RBC cells leukocytes reduced: a unit of whole blood contains = or
> 1-10 x 10 to the 9th white blood cells. Leukocyte-reduced blood is prepared by
filtering blood with special filters that remove white blood cells by sieving
and adherence mechanisms. Filtration may be done as follows: 1) soon after
collection (pre-storage), 2) after varying periods of storage in the laboratory,
or 3) at the bedside. The method used in the laboratory for leukocyte-reduction
is subject to quality control testing; leukocyte-reduced components prepared at
the bedside are not. Leukocyte reduction will decrease the cellular content and
volume of blood according to characteristics of the filter system used. Whole
blood, red blood cells, and platelets, pheresis leukocytes reduced must have a
residual content of leukocytes <5 x 10 to the 6th. Platelets leukocytes reduced
must have <8.3 x 10 to the 5th residual leukocytes. Leukocyte reduction filters
variably remove other cellular elements in addition to white blood cells.
Retention of 85% of the original therapeutic component is required. ****red
blood cells frozen and red blood cells rejuvenated frozen are prepared by adding
glycerol to red blood cells as a cryoprotective agent before freezing. The
glycerol must be removed from the thawed component before it is infused. Frozen
red cells may be stored for up to 10 years, and for longer intervals if there is
particular need for specific units. *****red blood cells deglycerolized is the
form in which cryo-preserved cells (red blood cells frozen) are available for
infusion. Red blood cells deglycerolized contain 80% or more of the red cells in
the original unit, and have approximately the same expected post transfusion
survival as red blood cells. This product's use should be restricted to red
cells with unusual antigenic phenotypes and for autologous donations when
liquid-preserved blood cannot fulfill demands. This product may also be useful
to patients with clinically significant immune reactivity against IgA. This
product carries the risk of intravascular hemolysis if deglycerolization has
been inadequate. |
